Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus and Sorafenib vs Sunitinib in Metastatic RCC
NCT01616186Phase 2Withdrawn
- Start
- Jul 2012
- Primary completion
- Dec 2015
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of everolimus, sorafenib in renal cell carcinoma (RCC). Planned start Jul 2012; status: withdrawn.
02
Drugs
everolimussorafenib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01616186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01616186.